Submit to IJMS Review for IJMS Propose a Special Issue

Journal Menu

Journal Browser

Frontiers in Psoriasis (PsO) and Psoriatic Arthritis (PSA)

Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Immunology".

Deadline for manuscript submissions: closed (15 December 2022) | Viewed by 9808

Share This Special Issue

Special Issue Editors

Prof. Dr. Adam Reich

E-Mail Website
Guest Editor

Department of Dermatology, Institute of Medical Sciences, Medical College of Rzeszow University, 35-959 Rzeszow, Poland
Interests: itch; psychodermatology; psoriasis; autoimmune connective tissue disorders
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Joanna Narbutt

E-Mail Website
Guest Editor

Department of Dermatology, Pediatric Dermatology and Dermatological Oncology, Medical University of Lodz, 91-347 Lodz, Poland
Interests: autoinflammatory and autoimmune skin diseases; photobiology and phototherapy
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Aleksandra Lesiak

E-Mail Website
Guest Editor

Department of Dermatology, Paediatric Dermatology and Oncology, Medical University of Lodz, Lodz, Poland
Interests: atopic dermatitis; urticaria; non-melanoma skin cancers; photocancerogenesis; psoriasis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Psoriasis is a chronic and recurrent disease with the prevalence of approximately 2–3% in the general population. Despite the scientific achievements over the last few decades, we still do not fully understand this disease. Significant improvements in psoriasis treatment are connected with the introduction of biological therapies that have changed patients’ lives; however, many questions still remain on how to enhance effectiveness of treatment based on molecular findings. The Special Issue “Psoriasis and Psoriatic Arthritis” will present the current knowledge on psoriasis and psoriatic arthritis with a special emphasis on pathogenesis and treatment. Articles on the genetics of psoriasis, biological markers (from skin to blood), and biological treatment (especially in relation to the outcomes of treatment) are welcome. The differential diagnosis of psoriatic arthritis can be a difficult one; thus, we would like to invite papers on this topic, as it can be a significant problem, especially in relation to osteoarthritis.

The Special Issue would like to follow the psoriatic patient’s journey into how the basic science may influence the treatment, using the translational medicine concept to give readers a deeper understanding of this complex disease.

Prof. Dr. Adam Reich
Prof. Dr. Joanna Narbutt
Prof. Dr. Aleksandra Lesiak
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

psoriasis
psoriatic arthritis
genetics
therapy
immunology
microbiota
blood

Published Papers (5 papers)

Download All Papers

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Research

20 pages, 4090 KiB

Open AccessArticle

Psoriatic Resolved Skin Epidermal Keratinocytes Retain Disease-Residual Transcriptomic and Epigenomic Profiles

by Ameneh Ghaffarinia, Ferhan Ayaydin, Szilárd Póliska, Máté Manczinger, Beáta Szilvia Bolla, Lili Borbála Flink, Fanni Balogh, Zoltán Veréb, Renáta Bozó, Kornélia Szabó, Zsuzsanna Bata-Csörgő and Lajos Kemény

Int. J. Mol. Sci. 2023, 24(5), 4556; https://doi.org/10.3390/ijms24054556 - 25 Feb 2023

Cited by 6 | Viewed by 2391

Abstract

The disease-residual transcriptomic profile (DRTP) within psoriatic healed/resolved skin and epidermal tissue-resident memory T (TRM) cells have been proposed to be crucial for the recurrence of old lesions. However, it is unclear whether epidermal keratinocytes are involved in disease recurrence. There is increasing evidence regarding the importance of epigenetic mechanisms in the pathogenesis of psoriasis. Nonetheless, the epigenetic changes that contribute to the recurrence of psoriasis remain unknown. The aim of this study was to elucidate the role of keratinocytes in psoriasis relapse. The epigenetic marks 5-methylcytosine (5-mC) and 5-hydroxymethylcytosine (5-hmC) were visualized using immunofluorescence staining, and RNA sequencing was performed on paired never-lesional and resolved epidermal and dermal compartments of skin from psoriasis patients. We observed diminished 5-mC and 5-hmC amounts and decreased mRNA expression of the ten-eleven translocation (TET) 3 enzyme in the resolved epidermis. SAMHD1, C10orf99, and AKR1B10: the highly dysregulated genes in resolved epidermis are known to be associated with pathogenesis of psoriasis, and the DRTP was enriched in WNT, TNF, and mTOR signaling pathways. Our results suggest that epigenetic changes detected in epidermal keratinocytes of resolved skin may be responsible for the DRTP in the same regions. Thus, the DRTP of keratinocytes may contribute to site-specific local relapse. Full article

(This article belongs to the Special Issue Frontiers in Psoriasis (PsO) and Psoriatic Arthritis (PSA))

► Show Figures

Figure 1

15 pages, 1489 KiB

Open AccessArticle

Topical Diacerein Decreases Skin and Splenic CD11c⁺ Dendritic Cells in Psoriasis

by Susanne M. Brunner, Andrea Ramspacher, Caroline Rieser, Julia Leitner, Hannah Heil, Michael Ablinger, Julia Tevini, Monika Wimmer, Andreas Koller, Josefina Piñón Hofbauer, Thomas K. Felder, Johann W. Bauer, Barbara Kofler, Roland Lang and Verena Wally

Int. J. Mol. Sci. 2023, 24(5), 4324; https://doi.org/10.3390/ijms24054324 - 21 Feb 2023

Viewed by 1843

Abstract

Psoriasis is an inflammatory skin disease characterized by increased neo-vascularization, keratinocyte hyperproliferation, a pro-inflammatory cytokine milieu and immune cell infiltration. Diacerein is an anti-inflammatory drug, modulating immune cell functions, including expression and production of cytokines, in different inflammatory conditions. Therefore, we hypothesized that topical diacerein has beneficial effects on the course of psoriasis. The current study aimed to evaluate the effect of topical diacerein on imiquimod (IMQ)-induced psoriasis in C57BL/6 mice. Topical diacerein was observed to be safe without any adverse side effects in healthy or psoriatic animals. Our results demonstrated that diacerein significantly alleviated the psoriasiform-like skin inflammation over a 7-day period. Furthermore, diacerein significantly diminished the psoriasis-associated splenomegaly, indicating a systemic effect of the drug. Remarkably, we observed significantly reduced infiltration of CD11c⁺ dendritic cells (DCs) into the skin and spleen of psoriatic mice with diacerein treatment. As CD11c⁺ DCs play a pivotal role in psoriasis pathology, we consider diacerein to be a promising novel therapeutic candidate for psoriasis. Full article

(This article belongs to the Special Issue Frontiers in Psoriasis (PsO) and Psoriatic Arthritis (PSA))

► Show Figures

Figure 1

13 pages, 308 KiB

Open AccessCommunication

Neutrophil Gelatinase-Associated Lipocalin as Potential Predictive Biomarker of Melanoma and Non-Melanoma Skin Cancers in Psoriatic Patients: A Pilot Study

by Alice Verdelli, Marzia Caproni, Alessio Coi, Alberto Corrà, Donatella Degl’Innocenti, Marzia Vasarri, Lavinia Quintarelli, Valter Volpi, Emanuele Maria Cipollini and Emanuela Barletta

Int. J. Mol. Sci. 2022, 23(20), 12291; https://doi.org/10.3390/ijms232012291 - 14 Oct 2022

Cited by 3 | Viewed by 1260

Abstract

Background: Studies have demonstrated a higher risk of nonmelanoma skin cancers (NMSC) and a modestly increased melanoma risk in patients with psoriasis. To date, no biomarkers predictive of evolution have been identified yet. Methods: The aim of this prospective case-control study was to investigate the potential role of neutrophil gelatinase-associated lipocalin (NGAL) as a predictive biomarker of skin cancers in psoriatic patients. Patients with a diagnosis of psoriasis were enrolled, as well as healthy subjects and patients with skin cancers as controls. Plasma protein expression of NGAL, metalloproteinases (MMP)-2, and MMP-9 was performed by an enzyme-linked immunosorbent assay (ELISA). In all the patients who developed skin cancer at follow-up, NGAL, MMP-2, and MMP-9 serum levels were dosed again. Results: Plasma NGAL levels were significantly higher in psoriatic patients with NMSC than without (182.3 ± 36.6 ng/mL vs. 139.9 ± 39.3 ng/mL) (p < 0.001). Plasma NGAL levels were significantly higher (p < 0.00001) in patients with psoriasis and NMSC than in patients with skin tumors without psoriasis (182.3 vs. 122.9). Patients with psoriasis who developed NMSC at follow-up showed increased plasma MMP-9 levels. Conclusion: NGAL seems to play a role in the pathogenesis of NMSC but not melanoma in patients with psoriasis. Full article

(This article belongs to the Special Issue Frontiers in Psoriasis (PsO) and Psoriatic Arthritis (PSA))

17 pages, 4670 KiB

Open AccessArticle

Impact of Comorbidities of Patients with Psoriasis on Phototherapy Responses

by Belén Fatás-Lalana, Joaquín Cantón-Sandoval, Lola Rodríguez-Ruiz, Raúl Corbalán-Vélez, Teresa Martínez-Menchón, Ana B. Pérez-Oliva and Victoriano Mulero

Int. J. Mol. Sci. 2022, 23(17), 9508; https://doi.org/10.3390/ijms23179508 - 23 Aug 2022

Cited by 2 | Viewed by 1975

Abstract

A retrospective study of 200 psoriasis patients and 100 healthy donors in a Spanish cohort was carried out to study the comorbidities associated with psoriasis and their association with the response to phototherapy. The results showed a higher incidence of psychiatric disease, liver disease, kidney disease, hypertension, heart disease, vascular disease, diabetes, gastrointestinal disease, autoimmune and infectious diseases, dyslipidemia, and psoriatic arthritis in patients with psoriasis than in the control group. The incidence of comorbidities was higher in psoriasis patients over 40 years old than in the control individuals of the same age, which could be indicative of premature aging. Phototherapy was seen to be an effective treatment in cases of moderate-severe psoriasis, total whitening being achieved in more than 30% of patients, with women showing a better response than men. Narrow-band ultraviolet B was found to be the most effective type of phototherapy, although achievement of PASI100 was lower in patients with liver disease, hypertension, heart disease, vascular disease, or diabetes. Strikingly, liver disease and anemia comorbidities favored therapeutic failure. Finally, zebrafish and human 3D organotypic models of psoriasis point to the therapeutic benefit of inhibiting the glucose transporter GLUT1 and the major regulator of blood glucose dipeptidyl peptidase 4. Our study reveals that specific comorbidities of psoriasis patients are associated to failure of phototherapy and, therefore, need to be considered when planning treatment for these patients. Full article

(This article belongs to the Special Issue Frontiers in Psoriasis (PsO) and Psoriatic Arthritis (PSA))

► Show Figures

Figure 1

9 pages, 1183 KiB

Open AccessCommunication

Phospholipase A1 Member A Deficiency Alleviates Mannan-Induced Psoriatic Arthritis in Mice Model

by Yang Zhao, Fawzi Aoudjit and Sylvain G. Bourgoin

Int. J. Mol. Sci. 2022, 23(15), 8559; https://doi.org/10.3390/ijms23158559 - 02 Aug 2022

Viewed by 1444

Abstract

Synovial fluids from rheumatoid and psoriatic arthritis patients have high levels of PLA1A. The current study was to understand PLA1A functions in the pathophysiology of rheumatic diseases. We generated Pla1a^−/− mice to assess their phenotype and the impact of PLA1A deficiency on the development of mannan-induced psoriatic arthritis (MIP). Mice were evaluated routinely for the induced symptoms. On the day of sacrifice, blood samples were collected for hematology analysis and prepared for plasma. Livers were collected. Lymph node immune cells were analyzed using flow cytometry. We performed μCT scans of hind paws from naïve and mannan-induced female mice. Cytokines/chemokines were quantified using Luminex in hind paw tissues and plasma of female mice. Pla1a^−/− mice showed a slight increase in circulating and lymph node lymphocytes. CD4⁺ T cells contributed most to this increase in lymph nodes (p = 0.023). In the MIP model, the lymph node ratios of CD3⁺ to CD19⁺ and CD4⁺ to CD8⁺ were higher in Pla1a^−/− mice. Pla1a^−/− mice were less susceptible to MIP (p < 0.001) and showed reduced bone erosions. Pla1a^−/− mice also showed reduced IL-17, KC, IP-10, MIP-1β, LIF, and VEGF in hind paw tissues as compared to WT mice (p < 0.05). These findings indicated that PLA1A deficiency protected from the development of the MIP disease. The data suggested that PLA1A could contribute to MIP through increased activation of lymphocytes, possibly those producing IL-17. Full article

(This article belongs to the Special Issue Frontiers in Psoriasis (PsO) and Psoriatic Arthritis (PSA))

► Show Figures

Journal Menu

Journal Browser

Frontiers in Psoriasis (PsO) and Psoriatic Arthritis (PSA)

Share This Special Issue

Special Issue Editors

Special Issue Information

Keywords

Published Papers (5 papers)

Research

Further Information

Guidelines

MDPI Initiatives

Follow MDPI